Showing posts with label osteoporosis drugs. Show all posts
Showing posts with label osteoporosis drugs. Show all posts

Most Taking Rx for Bone Drugs Quit

Certainly this is no surprise.  Osteoporosis drugs have many problematic and even life threatening side effects. They also require many lifestyle adjustments that after time many people, both men and women, find difficult.  Additionally many are fluoride based which causes the reduction or even ending of the function of osteoclast cells in your body.  Many severe fractures and jaw bone problems are linked to this drug function.



There are more natural things you can do to protect bone health.  And there are many natural approaches to keeping them strong and healthy.


Walking and weight bearing exercise are great!  Learn Tai Chi. Look into Lymphology at IAL.


A healthy diet and the right supplements are great! (Just don't be taking so much calcium.  Generally doctors tell you to take about twice what you need and the wrong type - carbonate).


Get hydrated!


Cut down on exposure to EMF and fluoride as well as other environmental toxins (the DEXA test is one of these and so is your cell phone).


Consider drinking nettle tea.


Consider using homeopathic cell salts.


Get tested for and take vitamin D3. (25 OH test)


Watch soy, it can block calcium, and is too often GMO.


Susan Brown PhD has been writing on this subject for years. Check out her book, Better Bones.
By Frederik JoelvingNEW YORK | Mon Feb 27, 2012 5:27pm EST(Reuters Health) - People with the bone-thinning condition osteoporosis often skip the drugs they are prescribed, and telephone counseling does little to change that, according to new research.
Researchers said osteoporosis is involved in more than two million fractures a year in the U.S., racking up medical costs of $19 billion.
In addition to exercise and a healthy diet with enough calcium and vitamin D, as well as measures to prevent falls, medications may reduce the risk of broken bones -- which can take a serious toll on the health of old people.
For people at high risk, bone drugs such as bisphosphonates may cut the yearly fracture risk from five percent to three percent, said Dr. Daniel Solomon of Brigham and Women's Hospital in Boston.
But people often stop taking the medications, added Solomon, also of Harvard Medical School.
"It's the problem with all chronic conditions," he told Reuters Health. "Drugs for asymptomatic chronic conditions are universally poorly adhered to."
Some 10 million Americans currently suffer from bone thinning, according to the National Osteoporosis Foundation. The majority are postmenopausal women.
Bone drugs include Merck's Fosamax, Roche's Boniva, Novartis's Reclast and Warner Chilcott's Actonel.
To see if they could convince people to take their drugs, Solomon and his colleagues divided more than 2,000 men and women with osteoporosis into two groups.
The participants were all on Medicare, the government's health insurance for the elderly, and got their meds for a co-pay of no more than a few dollars.
All of them received fall-prevention lifestyle tips in the mail from the researchers, and one group also had about eight counseling sessions over the phone.
During those sessions, trained counselors tried to identify why people skipped their drugs and to motivate them to get back on the treatment. The intervention ended up costing about $281 per patient, including training of the counselors.
After one year, there was little difference between the two groups.
Those who got counseling filled their prescriptions 49 percent of the time, while the others did so 41 percent of the time, based on claims data. That gap was too small to be reliable, statistically speaking.
The researchers didn't find any differences in how many people broke a bone or reported falls, either.
According to Solomon, people who skipped their medicine often said they had forgotten about it, didn't like the way it made them feel or didn't think they needed it.
Still, Solomon, whose findings appear in the Archives of Internal Medicine, wasn't willing to give up on counseling.
"It would be overstating the data to say that we should use this. What I'm saying is you don't want to throw the baby out with the bathwater," he said. "I think that counseling is something we need to continue to examine."
Researchers have been experimenting with a lot of ways to get people to take their drugs, including beeping pill caps and financial incentives, Solomon added. But the results have often been disappointing.
"At this point there really aren't any proven interventions," he said.
In an editorial, Dr. Seth Berkowitz and Dr. Kirsten Johansen of the University of California, San Francisco, say behavior change is an increasingly important part of medicine as chronic diseases continue rise.
"There is likely no 'magic bullet' in the behavior change arsenal in general or for increasing treatment adherence specifically," they write. "This does not mean, however, that the effects may not be clinically significant."
SOURCE: bit.ly/yMrnv4 Archives of Internal Medicine, February 27, 2012.
Selections from over 30 on Natural Health News

Feb 18, 2012
Osteoporosis drugs have many drawbacks. The same drugs have many risks including the risk of very bad fractures and having your jaw bone eaten away (necrosis). For the most part the drugs are fluoride based and cause ...
Dec 27, 2011
Researchers asked if “real-world” patients taking bone drugs received the same fracture-reduction benefits seen in the clinical trials. After analysis of hundreds of studies, they found that highly compliant, “real world” patients ...
Feb 03, 2010
New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. Women who already were using these medicines when ...
Nov 18, 2008
Bone Loss Problematic, Bone Drugs Risky. In January 2008 the FDA issued warnings regarding the class of drugs developed to allegedly help people with osteopenia and osteoporosis. Numerous problems are associated ...
Share:

How big is the bang from osteoporosis drugs?

From Susan Brown, PhD



Answering the question “how big is the bang from osteoporosis drugs?” can be quite challenging.
One reason is that the statistical calculations are complex and highly manipulated making them difficult to understand. Another is that the subjects included in the drug studies are generally highly-selected and may not represent “real-world” populations.
Recently scientists took an important step to help us separate hype from reality in regard to the benefits of bone drugs.
Researchers asked if “real-world” patients taking bone drugs received the same fracture-reduction benefits seen in the clinical trials. After analysis of hundreds of studies, they found that highly compliant, “real world” patients on osteoporosis drugs experienced a 21% reduction in all clinical fractures. This compares to the 24% overall clinical fracture reduction experienced by subjects in osteoporosis drug clinical trials.
What a different messages than we often hear — such as how bone drugs reduce your chance of fracture by 50%! Or have you ever been told that the fracture reduction on bone drugs is really more like 21-24%? That is — if you use the drug faithfully.
Now compare this 21-24% fracture-reduction benefit from bone drugs to the studies documenting that those taking vitamin D in any dose (much less a therapeutic dose) experience a 23-26% reduction in fractures. It seems to me that the bang from osteoporosis drugs isn’t quite as big as we’ve been led to believe.
As your bone health advocate, I congratulate these researchers on the enormous effort to analyze and synthesize data from hundreds of studies. I also congratulate the drug company which funded this study for clarifying the real fracture/reduction benefit of today’s bone drugs.

References:
Wilkes, et al. 2010. “Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials.” Osteoporosis International 21:679-688
Bischoff-Ferrari, HA et al. 2005. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA, 293(18): 2257-2264

The Week in Bone Health | How big is the bang from osteoporosis drugs?


Selections from Natural Health News

Sep 06, 2011
The osteoporosis drug zoledronic acid (Reclast) should not be used in patients with significant renal impairment, and physicians should screen patients for kidney dysfunction before starting them on the drug, the FDA said. ...
Aug 16, 2009
Another Big PhARMA fiasco, as all the current osteoporosis drugs seem to be. Of course you don't hear too much about their fluoride content and how this damages the thyroid and bone health, but then how would they mask ...
Oct 02, 2009
Osteoporosis drug Forteo linked with bone cancer. BLACK BOX WARNING FOR FORTEO, a gentically engineered pharmaceutical. POTENTIAL RISK OF OSTEOSARCOMA: In male and female rats, teriparatide caused an ...
Jan 24, 2009
***Just remember that as bone density leads to brittle bones and fracture, so do the prescription osteoporosis drugs. ... Part of this missing link is the bone-damaging impact from many non-osteoporosis drugs. Another is that ...
Share: